From wiki:
Imugene began as a research project in the laboratory of Professor Ursula Wiedermann at the Medical University of Vienna. Over the nine years from 2004 Wiedermann et al. had developed a B cell peptide cancer immunotherapy that could induce an antibody response targeting HER-2 overexpressing tumours. In 2012 a start-up company called Biolife Science had been incorporated to develop this immunotherapy. Early-stage funding was secured from Australian and US investors in 2013, after which Biolife was taken public in December 2013 in a reverse takeover of an Australian drug development company called Imugene, whose name was retained after the merger
Charting Only., page-2349
-
-
- There are more pages in this discussion • 177 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.7¢ |
Change
0.002(3.64%) |
Mkt cap ! $417.2M |
Open | High | Low | Value | Volume |
5.6¢ | 5.9¢ | 5.5¢ | $1.176M | 20.89M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 1135235 | 5.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.8¢ | 477220 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 1135235 | 0.056 |
16 | 3594783 | 0.055 |
25 | 2690034 | 0.054 |
14 | 2508989 | 0.053 |
19 | 1508511 | 0.052 |
Price($) | Vol. | No. |
---|---|---|
0.058 | 477220 | 6 |
0.059 | 1583318 | 9 |
0.060 | 1596698 | 18 |
0.061 | 1828886 | 10 |
0.062 | 3277833 | 9 |
Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |